Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 10 11 12 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
CureVac–myNEO: drug target discovery, 202205– collab research + option agreem antigen targets for mRNA cancer vaccines 2022-05-25
Alithea Genomics–Novalis Biotech: investment, 202205 seed financing round totalling CHF1m incl lead investor Novalis Biotech Acceleration Fund 2022-05-24
Alithea Genomics–OTHER: investment, 202205 seed financing round totalling CHF1m incl Swiss-based private investors as co-investors 2022-05-24
Alithea Genomics–SEVERAL: investment, 202205 seed financing round CHF1m led by Novalis Biotech Acceleration Fund 2022-05-24
Almirall–Evotec: drug discovery services, 202205– collab multi-target RnD alliance in medical dermatology 2022-05-19
Apollo Global Management–Sofinnova: life science financing, 202205– strategic partnership incl investm in Sofinnova Partners + up to $1b capital 2022-05-16
HH2E–Foresight Group: investment, 202205 financing round totalling at least €12m incl Foresight Group acquiring minority share 2022-05-16
HH2E–HydrogenOne Capital: investment, 202205 financing round totalling at least €12m incl HydrogenOne Capital acquiring minority share 2022-05-16
HH2E–SEVERAL: investment, 202205 financing round at least €12m with HydrogenOne Capital + Foresight Group aquiring minoirty stakes ANNOUNCED 2022-05-16
Proteros–Trophic Communications: public relations, 202205 service existent by Trophic 2022-05-16
Sofinnova–Apollo Global Management: investment, 202205– acquisition of minority equity interest in Sofinnova Partners as part of strategic partnership 2022-05-16
Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo 2022-05-16
Enzymaster–SEVERAL: investment, 202205 financing round Series C over $45m (CYN300m) led by Yuanbio Venture Capital 2022-05-12
BLIRT–Qiagen: investment, 202205 acquisition 96% ownership stake by Qiagen 2022-05-11
Biohaven Pharmaceuticals–HBM: investment, 202205 investment existent worth $67m at time of announced $11.6b acquisition of Biohaven by Pfizer 2022-05-10
Biohaven Pharmaceuticals–Pfizer: investment, 202205– acquisition $11.6b in cash at $148.5/share excluding non-CGRP pipeline ANNOUNCED 2022-05-10
Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund 2022-05-10
Sidekick Health–SEVERAL: investment, 202205 financing round Series B $55m led by Novator Ventures 2022-05-05
Sidekick Health–Wellington Partners: investment, 202205 financing round Series B totalling $55m incl existing + co-investor Wellington Partners 2022-05-05
Engimmune Therapeutics–Bellevue: investment, 202205 seed financing round totalling CHF15.5m incl co-lead investor Pureos Bioventures 2022-05-03
Engimmune Therapeutics–Novo Group: investment, 202205 seed financing round totalling CHF15.5m incl co-lead investor Novo Seeds 2022-05-03
Engimmune Therapeutics–SEVERAL: investment, 202205 seed financing round CHF15.5m co-led by Pureos Bioventures + Novo Seeds 2022-05-03
Tubulis–Andera Partners: investment, 202205 financing round Series B totalling €60m incl new + lead investor Andera Partners 2022-05-03
Tubulis–Bavaria (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Wachstumsfonds Bayern 2 2022-05-03
Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners 2022-05-03
Tubulis–BPCE: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Seventure Partners 2022-05-03
Tubulis–Evotec: investment, 202205 financing round Series B totalling €60m incl new + co-investor Evotec 2022-05-03
Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+ 2022-05-03
Tubulis–Germany (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Coparion 2022-05-03
Tubulis–High-Tech Gründerfonds: investment, 202205 financing round Series B totalling €60m incl existing + co-investor HTGF 2022-05-03
Tubulis–Occident: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident 2022-05-03
Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners 2022-05-03
Amply Discovery–SEVERAL: investment, 202205 pre-seed financing round 2022-05-01
Bionter–Dynamk Capital: investment, 202204 Series Seed financing $3m from Dynamk Capital 2022-04-27
Boehringer–Roivant: AI-based drug discovery, 202204– collab research €na with VantAI using AI/ML to identify protein degraders 2022-04-20
Boehringer–CDR-Life: ophthalmic, 202204 collab development existent of antibody fragment-based therapeutic CDR202 for macular degeneration 2022-04-13
CDR-Life–Argot Partners: public relations, 202204 service existent media contact Argot Partners 2022-04-13
CDR-Life–Jeito Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor Jeito Capital 2022-04-13
CDR-Life–Omega Funds: investment, 202204 financing round Series A totalling $76m incl co-investor Omega Funds 2022-04-13
CDR-Life–RA Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor RA Capital Management 2022-04-13
CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital 2022-04-13
Cimeio Therapeutics–Versant Ventures: investment, 202204– Series A $50m commitment at launch from Versant Ventures 2022-04-13
Sierra Oncology–HBM: investment, 202204 existent investment of HBM at time of announced $1.9b acquisition of Sierra Oncology by GSK 2022-04-13
Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED 2022-04-12
Enable Medicine–SEVERAL: investment, 202204 financing round Series A $60m led by Anthos Capital + General Catalyst 2022-04-07
Avi Medical–Balderton Capital: investment, 202204 financing round Serise B totalling €50m incl lead investor Balderton Capital 2022-04-06
Avi Medical–SEVERAL: investment, 202204 financing round Series B €50m led by Balderton Capital 2022-04-06
IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker 2022-04-06
Regeneron–ViGeneron: gene therapy, 202204– collab + option agreem to develop vgAAV-based therapeutics for one inherited retinal disease target 2022-04-06
Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza 2022-04-05
Optimal Industrial–Bruker: investment, 202204 acquisition €na of Optimal Industrial Automation + Technologies by Bruker 2022-04-05
Boehringer–Celeris Therapeutics: targeted protein degraders, 202204– collab AI-based drug discovery for target of Boehringer 2022-04-04
Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m 2022-04-04
Andes–Bayer: investment, 202204 existent portfolio company of Leaps by Bayer 2022-04-01
Biovox–SEVERAL: investment, 202204 pre-seed financing round with mid-6-figure € amount from business angels 2022-04-01
Ebenbuild–Bavaria (govt): investment, 202203 seed financing round totalling €2.5m incl co-lead investor Bayern Kapital 2022-03-31
Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF 2022-03-31
Ebenbuild–OTHER: investment, 202203 seed financing round totalling €2.5m incl well-known business angels as co-investors 2022-03-31
Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels 2022-03-31
Immunic–4SC: vidofludimus, 202103 settlement of remaining royalty obligations for IMU-838 for $17.25m with 50% in cash + 50% in Immunic common stock 2022-03-31
Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan 2022-03-30
Neuron23–HBM: investment, 202203 financing round Series C totalling $100m incl existing + co-investor HBM Partners 2022-03-30
Neuron23–SEVERAL: investment, 202203 financing round Series C $100m led by SoftBank Vision Fund 2 2022-03-30
VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m 2022-03-30
Core Biogenesis–Thia Ventures: investment, 202203 financing round Series A totalling €10m incl new + co-investor Thia Ventures 2022-03-29
Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation 2022-03-29
Innovacell–EU (govt): credit, 202203– venture debt loan of up to €15m from EIB to Innovacell AG 2022-03-24
Irubis–EU (govt): credit, 202203– convertible loan €500k from EIC Fund as part of EIC Accelerator Pilot programme 2022-03-24
Immatics–Trophic Communications: public relations, 202203 service existent by Trophic 2022-03-23
Aerium Therapeutics–F-Prime: investment, 202203 financing round Series A incl new + co-investor F-Prime Capital 2022-03-22
Aerium Therapeutics–Omega Funds: investment, 202203 financing round Series A incl existing seed + lead investor Omega Funds 2022-03-22
Aerium Therapeutics–SEVERAL: investment, 202203 emerges with substantial financing round Series A led by seed investor Omega Funds 2022-03-22
Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer 2022-03-22
ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada 2022-03-22
ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc 2022-03-22
ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc 2022-03-22
Nucleai MD–Debiopharm: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Debiopharm 2022-03-22
Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures 2022-03-22
Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant 2022-03-21
BigOmics–Eppendorf: investment, 202203 investment from Eppendorf Innovation Company (EpIC) closes pre-Series A round 2022-03-17
Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund 2022-03-16
Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion 2022-03-16
BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients 2022-03-15
InfanDx–SEVERAL: investment, 202203 financing round Series A 2nd closing €2m from new + existing investors bringing total Series A to €6m 2022-03-15
PrognomiQ–Bruker: investment, 202203 financing round totalling $46m incl lead investor Bruker Corp 2022-03-15
PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp 2022-03-15
Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl 2022-03-14
Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH 2022-03-14
Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank 2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH 2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH 2022-03-14
Ayoxxa–Prosnav Capital: investment, 202203– financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital NOT REALISED 2022-03-14
Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office 2022-03-14
Ayoxxa–SEVERAL: investment, 202203– financing round providing runway for 3-5 years led by new investor Prosnav Capital NOT REALISED 2022-03-14
Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners 2022-03-14
FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED 2022-03-14
Ginkgo Bioworks–FGen: screening technology, 202203 collab existent for several years 2022-03-14
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Matthias Bissinger 2022-03-10
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Philipp Baaske 2022-03-10
Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech 2022-03-10
next pagenext page 1 2 3 ... 10 11 12 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top